Substance / Medication

Osilodrostat

Overview

Active Ingredient
osilodrostat
RxNorm CUI
2286252

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

No related conditions have been mapped yet. Condition-intervention linkages are derived from SNOMED CT relationships and will expand as the knowledge graph grows.

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
2
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Adverse Event Profile Differences Between Metyrapone and Osilodrostat: A Pharmacovigilance Study of the FDA Adverse Event Reporting System.
Xia Chunyong, Hu Lanxin, Fan Ying et al. · Horm Metab Res · 2025
PMID: 40825365Observational
Matching-Adjusted Indirect Comparison of Osilodrostat Versus Metyrapone for the Treatment of Cushing's Syndrome.
Hickey Conor, Gueron Beatrice, Schmidt Fabian et al. · Adv Ther · 2025
PMID: 40439958Observational
Chronotherapy With Once-Daily Osilodrostat Improves Cortisol Rhythm, Quality of Life, and Sleep in Cushing's Syndrome.
Ferrari Davide, Bonaventura Ilaria, Simeoli Chiara et al. · J Clin Endocrinol Metab · 2025
PMID: 40172910ObservationalFull text (PMC)
Long-term efficacy and safety of osilodrostat in patients with Cushing's disease: results from the LINC 4 study extension.
Gadelha Mônica, Snyder Peter J, Witek Przemysław et al. · Front Endocrinol (Lausanne) · 2023
PMID: 37680892ObservationalFull text (PMC)
Efficacy and Safety of Osilodrostat in Paraneoplastic Cushing Syndrome: A Real-World Multicenter Study in France.
Dormoy Alexandre, Haissaguerre Magalie, Vitellius Géraldine et al. · J Clin Endocrinol Metab · 2023
PMID: 36470583ObservationalFull text (PMC)
Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension.
Fleseriu Maria, Newell-Price John, Pivonello Rosario et al. · Eur J Endocrinol · 2022
PMID: 35980235ObservationalFull text (PMC)
A case of prolonged adrenal insufficiency following osilodrostat discontinuation with a review of the literature.
Kaniuka-Jakubowska Sonia, Kunc Michał, Maksymowicz Maria et al. · Endocr J · 2026
PMID: 41139506Case ReportFull text (PMC)
Successful Treatment of Severe Ectopic ACTH-Dependent Cushing Syndrome Complicated by Hypocalcemia With Osilodrostat.
Lee Kristen, Mendes Pessoa Carolina, Huang Wenyu · JCEM Case Rep · 2025
PMID: 39839756Case ReportFull text (PMC)
Prolonged Adrenal Insufficiency After Failed Cryoablation and Osilodrostat for Cushing Syndrome in Nodular Adrenal Disease.
Veloski Colleen, Sturgeon Amanda, Hallanger Johnson Julie · JCEM Case Rep · 2025
PMID: 40303510Case ReportFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Osilodrostat (substance)
SNOMED CT
863916001
UMLS CUI
C4330903
RxNorm CUI
2286252

Clinical Data

This intervention maps to 0 entities in the Ltrl knowledge graph.

0
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.